文献速递脑血管病

卒中中枢神经系统药物递送:改善从实验室到临床的转化

CNS Drug Delivery in Stroke: Improving Therapeutic Translation From the Bench to the Bedside.
PubMed 文献 · Stroke · 2023-12-22

本综述指出缺血性卒中药物研发面临III期试验后候选药物匮乏的困境,强调有效脑内递送是神经保护疗效的关键。文章阐述血脑屏障(BBB)/神经血管单元病理生理,并描述被动扩散、机械开放BBB、脂质体/纳米颗粒、转胞吞、鼻内给药等中枢神经系统递送优化策略,以及内源性BBB转运体作为下一前沿。

要点

  • 有效脑内递送是缺血性卒中神经保护药物发挥疗效的关键条件。
  • 理解BBB/神经血管单元生物学有助于优化卒中治疗药物的 bench-to-bedside 转化。
  • 内源性BBB转运体被视为卒中药物递送策略的下一前沿。

核心结论

  • 本综述强调中枢神经系统药物递送必须被纳入新卒中药物向人体试验推进的考量。
  • 有效脑内递送对多种小分子和大分子药物的神经保护疗效至关重要。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 缺血性卒中药物研发挑战在于少有治疗药物推进至III期试验之后。
  • 临床转化不足的原因包括临床前研究实验设计相关因素。
  • 综述描述了被动扩散、机械开放BBB、脂质体/纳米颗粒、转胞吞、鼻内给药等中枢神经系统递送优化方法。
  • 内源性BBB转运体代表卒中药物递送策略的下一前沿。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Drug development for ischemic stroke is challenging as evidenced by the paucity of therapeutics that have advanced beyond a phase III trial. There are many reasons for this lack of clinical translation including factors related to the experimental design of preclinical studies. Often overlooked in therapeutic development for ischemic stroke is the requirement of effective drug delivery to the brain, which is critical for neuroprotective efficacy of several small and large molecule drugs. Advancing central nervous system drug delivery technologies implies a need for detailed comprehension of the blood-brain barrier (BBB) and neurovascular unit. Such knowledge will permit the innate biology of the BBB/neurovascular unit to be leveraged for improved bench-to-bedside translation of novel stroke therapeutics. In this review, we will highlight key aspects of BBB/neurovascular unit pathophysiology and describe state-of-the-art approaches for optimization of central nervous system drug delivery (ie, passive diffusion, mechanical opening of the BBB, liposomes/nanoparticles, transcytosis, intranasal drug administration). Additionally, we will discuss how endogenous BBB transporters represent the next frontier of drug delivery strategies for stroke. Overall, this review will provide cutting edge perspective on how central nervous system drug delivery must be considered for the advancement of new stroke drugs toward human trials.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Ronaldson PT, Williams EI, Betterton RD, et al. CNS Drug Delivery in Stroke: Improving Therapeutic Translation From the Bench to the Bedside. Stroke. 2023. PMID: 38134249. doi:10.1161/STROKEAHA.123.043764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。